Drupal.behaviors.print = function(context) {window.print();window.close();}>

Febit, Nearing Settlement with Codon Devices, Reconsiders Its Place in Synthetic Bio Market

April 14, 2009

Febit, Nearing Settlement with Codon Devices, Reconsiders Its Place in Synthetic Bio Market

By Justin Petrone

"We don't want to be part of a commodity market with a lot of close competition," said Peer Stähler, Febit's chief scientific officer. "There are at least 20 companies worldwide that are competing to sell the cheapest genes."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.

Related Stories